Taro Pharmaceutical Industries Earns RS Rating Upgrade – Investor's Business Daily

This post was originally published on this site

In a welcome move, Taro Pharmaceutical Industries (TARO) saw its Relative Strength Rating improve from 69 to 72 on Monday.

XAutoplay: On | Off This proprietary rating measures technical performance by showing how a stock’s price action over the last 52 weeks compares to that of the other stocks in our database.

Decades of market research reveals that the top-performing stocks often have an 80 or higher RS Rating as they launch their biggest climbs. See if Taro Pharmaceutical Industries can continue to rebound and hit that benchmark.


See How IBD Helps You Make More Money In Stocks


Taro Pharmaceutical Industries is not currently offering a proper buying opportunity. See if the stock goes on to form a promising consolidation that could ignite a new run.

Earnings-per-share growth decreased in the company’s latest report from -48% to -57%, but sales rose from -31% to -26%.

Taro Pharmaceutical Industries holds the No. 8 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals (ANIP), Neos Therapeutics (NEOS) and Lannett (LCI) are among the top 5 highly rated stocks within the group.

RELATED:

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

This post was originally published on *this site*